Clinical trial

IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma

NCT00349934

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2006-07-01

PhasePHASE1

Study timeline

Study start (unknown)2006-07-01Date precision: month

Registry last updated2010-01-07

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metastatic Breast Cancerunresolved

Interventions

IMP321BIOLOGICAL

Sponsors & collaborators

Immutep S.A.S.lead sponsor

Umaniscollaborator

Mapped research locations

ParisFrance2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00349934 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.